silibinin + ribavirin

Silibinin + ribavirin is an investigational combination therapy for chronic hepatitis C virus (HCV) infection, most commonly studied as part of a regimen for treatment-experienced or non-responder patients, particularly post-liver transplantation. Silibinin is a flavonolignan derived from milk thistle (*Silybum marianum*) with demonstrated *antiviral* and *anti-oxidative* effects. It acts by inhibiting HCV RNA-dependent RNA polymerase, thus interfering with viral replication, and may sensitize patients to interferon by reducing oxidative stress. Ribavirin is a nucleoside analog that works as a broad-spectrum antiviral, primarily by inhibiting viral RNA synthesis. The combination, sometimes used alongside pegylated interferon, has improved virological response rates in several studies, especially for HCV genotype 3 patients after transplantation. Administration may be intravenous or oral for silibinin, and oral for ribavirin. Adverse effects include pruritus and anemia, sometimes requiring erythropoietin support. Clinical trials have evaluated sustained virological response (SVR) as the key endpoint, with some patients achieving SVR 24 weeks after therapy. Legalon SIL is the main intravenous formulation of silibinin used in clinical studies[1][2][4][5][6].